Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease.
Aberrant DNA methylation occurs early in oncogenesis, is stable, and can be assayed in tissues and body fluids. Therefore, genes with aberrant methylation can provide clues for understanding tumor pathways and are attractive candidates for detection of early neoplastic events. Identification of sequences that optimally discriminate cancer from other diseased and healthy tissues is needed to advance both approaches. Using well-characterized specimens, genome-wide methylation techniques were used to identify candidate markers specific for colorectal neoplasia. To further validate 30 of these candidates from genome-wide analysis and 13 literature-derived genes, including genes involved in cancer and others with unknown functions, a high-throughput methylation-specific oligonucleotide microarray was used. The arrays were probed with bisulfite-converted DNA from 89 colorectal adenocarcinomas, 55 colorectal polyps, 31 inflammatory bowel disease, 115 extracolonic cancers, and 67 healthy tissues. The 20 most discriminating markers were highly methylated in colorectal neoplasia (area under the receiver operating characteristic curve > 0.8; P < 0.0001). Normal epithelium and extracolonic cancers revealed significantly lower methylation. Real-time PCR assays developed for 11 markers were tested on an independent set of 149 samples from colorectal adenocarcinomas, other diseases, and healthy tissues. Microarray results could be reproduced for 10 of 11 marker assays, including eight of the most discriminating markers (area under the receiver operating characteristic curve > 0.72; P < 0.009). The markers with high specificity for colorectal cancer have potential as blood-based screening markers whereas markers that are specific for multiple cancers could potentially be used as prognostic indicators, as biomarkers for therapeutic response monitoring or other diagnostic applications, compelling further investigation into their use in clinical testing and overall roles in tumorigenesis.
Model
Fabian
F
Epigenomics, Inc., Suite 300, 1000 Seneca Street, Seattle, WA 98101, USA.
Osborn
Neal
N
Ahlquist
David
D
Gruetzmann
Robert
R
Molnar
Bela
B
Sipos
Ferenc
F
Galamb
Orsolya
O
Pilarsky
Christian
C
Saeger
Hans-Detlev
HD
Tulassay
Zsolt
Z
Hale
Kari
K
Mooney
Suzanne
S
Lograsso
Joseph
J
Adorjan
Peter
P
Lesche
Ralf
R
Dessauer
Andreas
A
Kleiber
Joerg
J
Porstmann
Baerbel
B
Sledziewski
Andrew
A
Lofton-Day
Catherine
C
D014408:Biomarkers, Tumor / Q000032:analysis*; D016000:Cluster Analysis; D015179:Colorectal Neoplasms / Q000145:classification / Q000378:metabolism*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000378:metabolism*; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D016133:Polymerase Chain Reaction
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm